SpyGlass Pharma, Inc.: shareholders and insiders

SGPNASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$30.43

November 20, 2026Market cap $1.0B

What Ploutos Investor adds for SpyGlass Pharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 2 fiscal years, from 2024
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Feb 9, 2026 to Nov 18, 2026, from their own Form 4 filings.

2 Form 4s

Bought on the market

$84M

6 people

Sold on the market

–

nobody

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

  • Nov 16, 2026Ra Capital Management, L.p.Director
    Kind
  • Nov 16, 2026Kirk G. NielsenDirector
    Kind
  • Nov 16, 2026Kirk G. NielsenDirector
    Kind
  • Nov 16, 2026Kirk G. NielsenDirector
    Kind
  • Feb 9, 2026Paul Edward Walker
    Kind
  • Feb 9, 2026RA Capital Healthcare Fund LP
    Kind
  • Feb 9, 2026RA Capital Healthcare Fund LP
    Kind
  • Feb 9, 2026Geoffrey B Pardo
    Kind
  • Feb 9, 2026Bilal Arshad Khan
    Kind
  • Feb 9, 2026Bilal Arshad Khan
    Kind
  • Feb 9, 2026Vensana Capital I GP, LLC
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Nov 18, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

6 Holders over 5%4 On a 13DFeb 17, 2026 Latest filing
  • RA Capital Management, L.P.with 4 more persons
    Share of class24.1%
  • New Enterprise Associates 17, L.P.with 14 more persons
    Share of class22.2%
  • Vensana Capital I GP, LLCwith 3 more persons
    Share of class9.90%
  • Sands Capital Life Sciences Pulse Fund III (DE), L.P.with 3 more persons
    Share of class7.80%
  • Gilde Healthcare Holding B.V.with 4 more persons
    Share of class6.57%
  • Samsara BioCapital, L.P.with 4 more persons
    Share of class6.30%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • RA Capital Management, L.P.24.1%From the filing of Feb 17, 2026

    The Reporting Persons acquired the common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, and could involve the monetization of potential revenue streams deriving from development-stage or commercial programs of the Issuer, or dispose of Issuer…

    From the filing of Feb 17, 2026
  • New Enterprise Associates 17, L.P.22.2%From the filing of Feb 13, 2026

    The Funds acquired the Firm Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, the Funds and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a…

    From the filing of Feb 13, 2026
  • Vensana Capital I GP, LLC9.9%From the filing of Feb 10, 2026

    The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other…

    From the filing of Feb 10, 2026
  • Gilde Healthcare Holding B.V.6.6%From the filing of Feb 13, 2026

    The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other…

    From the filing of Feb 13, 2026

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Millennium Mgmt (Englander)
    In the quarter-17%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 3.66% of its shares outstanding were held short, -2.3% since the report before.

Shares held short
1.22M
3.66%
Since the report before1.25M on Sep 30, 2026
-2.3%
15.7
78.2K
More days to cover thanof 4,578 US-listed companies with enough volume
98%
Report date
Oct 15, 2026
  • Feb 13, 2026: Shares held short 181.1K
  • Feb 27, 2026: Shares held short 319.3K
  • Mar 13, 2026: Shares held short 567.4K
  • Mar 31, 2026: Shares held short 962.4K
  • Apr 15, 2026: Shares held short 1.04M
  • Apr 30, 2026: Shares held short 884.6K
  • May 15, 2026: Shares held short 858.6K
  • May 29, 2026: Shares held short 1.14M
  • Jun 15, 2026: Shares held short 1.01M
  • Jun 30, 2026: Shares held short 1.31M
  • Jul 15, 2026: Shares held short 1.13M
  • Jul 31, 2026: Shares held short 1.14M
  • Aug 14, 2026: Shares held short 1.14M
  • Aug 31, 2026: Shares held short 1.10M
  • Sep 15, 2026: Shares held short 1.23M
  • Sep 30, 2026: Shares held short 1.25M
  • Oct 15, 2026: Shares held short 1.22M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading48.6% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 48.6% of the shares in the reported trades were short sales, against 63.4% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
48.6%
The 14 beforeOct 14, 2026 – Nov 2, 2026
63.4%
Change
-14.8 pts
Short sales a dayon average, of 63.2K shares
30.7K
More than atof 3,666 US-listed companies, same days
43%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 78.8%
  • Oct 15, 2026: Short sales 82.8%
  • Oct 16, 2026: Short sales 94.7%
  • Oct 19, 2026: Short sales 85%
  • Oct 20, 2026: Short sales 53.9%
  • Oct 21, 2026: Short sales 54.1%
  • Oct 22, 2026: Short sales 65%
  • Oct 23, 2026: Short sales 52.2%
  • Oct 26, 2026: Short sales 76.4%
  • Oct 27, 2026: Short sales 65.6%
  • Oct 28, 2026: Short sales 61.2%
  • Oct 29, 2026: Short sales 37.8%
  • Oct 30, 2026: Short sales 65.3%
  • Nov 2, 2026: Short sales 84%
  • Nov 3, 2026: Short sales 48.2%
  • Nov 4, 2026: Short sales 23.1%
  • Nov 5, 2026: Short sales 48%
  • Nov 6, 2026: Short sales 49.9%
  • Nov 9, 2026: Short sales 13.7%
  • Nov 10, 2026: Short sales 43.7%
  • Nov 11, 2026: Short sales 54.5%
  • Nov 12, 2026: Short sales 72.8%
  • Nov 13, 2026: Short sales 56.7%
  • Nov 16, 2026: Short sales 87%
  • Nov 17, 2026: Short sales 84.7%
  • Nov 18, 2026: Short sales 50%
  • Nov 19, 2026: Short sales 77.3%
  • Nov 20, 2026: Short sales 78.1%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

83.09M Insiders' shares248.59% Of the company
  • Ra Capital Management, L.p.Director
    Directly8.02M
  • Paul Edward WalkerTenPercentOwner
    Directly–
  • Carmen ChangTenPercentOwner
    Directly–
  • Edward T MathersTenPercentOwner
    Directly–
  • Scott D SandellTenPercentOwner
    Directly–
  • Mohamad MakhzoumiTenPercentOwner
    Directly–
  • Rick YangTenPercentOwner
    Directly–
  • Nea 17 Gp, LlcTenPercentOwner
    Directly6.04M
  • Forest BaskettTenPercentOwner
    Directly–
  • Anthony A. Florence Jr.TenPercentOwner
    Directly–
  • Ali BehbahaniDirector,TenPercentOwner
    Directly–
  • RA Capital Healthcare Fund LPDirector,TenPercentOwner
    Directly–
  • Vensana Capital I GP, LLCTenPercentOwner
    Directly–
  • Kirk G. NielsenDirector
    Directly2.98M
  • Geoffrey B PardoDirector
    Directly–
  • Bilal Arshad KhanDirector
    Directly25.5K

A lower bound: it counts only the 16 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

9 ETFs holding it0.05% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.05%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.01%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.01%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.01%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.01%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.00%
  • VTIVanguard Total Stock Market Index Fund
    Weight in the fund0.00%
  • SCHBSchwab U.S. Broad Market ETF
    Weight in the fund0.00%

9 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

52 Managers, Q2 2026$581M Value of their positions
  • Q1 2026: Managers 35
  • Q2 2026: Managers 52

Q2 2026: 52 managers held 26.12M shares, worth $581M. During the quarter 22 opened a position, 5 closed one, 16 added and 4 trimmed.

The largest holders, Q2 2026

  • Ra Capital Management
    In the quarter
  • NEA Management
    In the quarter
  • Sands Capital Alternatives
    In the quarter
  • Samsara Biocapital
    In the quarter
  • BlackRock
    In the quarter+392%
  • Price T Rowe Associates
    In the quarter-4.3%
  • Vestal Point Capital
    In the quarter+0.5%
  • JPMorgan Chase
    In the quarter+9.1%
  • Deerfield Management
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter+8.2%

From the SEC's Form 13F data sets, Q1 2026 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do SpyGlass Pharma's filings show?

Who buys and sells is one part of SpyGlass Pharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about SGP's shareholders

Didn't find what you were looking for?

Ask us
Have SGP's insiders bought or sold?

From Nov 18, 2026 to Nov 18, 2026 SpyGlass Pharma's insiders bought $32.4K and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.

Which well-known managers hold SGP?

1 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $11M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.